Efficacy of a drug-eluting stent versus bare metal stents for symptomatic femoropopliteal peripheral artery disease: primary results of the EMINENT randomized trial
Y Gouëffic, G Torsello, T Zeller, G Esposito… - Circulation, 2022 - Am Heart Assoc
Background: A clear patency benefit of a drug-eluting stent (DES) over bare metal stents
(BMSs) for treating peripheral artery disease of the femoropopliteal segment has not been …
(BMSs) for treating peripheral artery disease of the femoropopliteal segment has not been …
Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized …
Y Gouëffic, G Torsello, T Zeller, G Esposito… - …, 2022 - ingentaconnect.com
Background: A clear patency benefit of a drug-eluting stent (DES) over bare metal stents
(BMSs) for treating peripheral artery disease of the femoropopliteal segment has not been …
(BMSs) for treating peripheral artery disease of the femoropopliteal segment has not been …
Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized …
Y Gouëffic, G Torsello, T Zeller, G Esposito… - Circulation, 2022 - boris.unibe.ch
BACKGROUND A clear patency benefit of a drug-eluting stent (DES) over a bare metal stent
(BMS) for treating peripheral artery disease of the femoropopliteal segment has not been …
(BMS) for treating peripheral artery disease of the femoropopliteal segment has not been …
Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized …
Y Goueffic, G Torsello, T Zeller, G Esposito… - …, 2022 - epub.ub.uni-muenchen.de
BACKGROUND: A clear patency benefit of a drug-eluting stent (DES) over bare metal stents
(BMSs) for treating peripheral artery disease of the femoropopliteal segment has not been …
(BMSs) for treating peripheral artery disease of the femoropopliteal segment has not been …
Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized …
Y Gouëffic, G Torsello, T Zeller, G Esposito… - 2022 - pubmed.ncbi.nlm.nih.gov
Background A clear patency benefit of a drug-eluting stent (DES) over bare metal stents
(BMSs) for treating peripheral artery disease of the femoropopliteal segment has not been …
(BMSs) for treating peripheral artery disease of the femoropopliteal segment has not been …
Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized …
Y Gouëffic, G Torsello, T Zeller, G Esposito… - Circulation, 2022 - Am Heart Assoc
BACKGROUND: A clear patency benefit of a drug-eluting stent (DES) over bare metal stents
(BMSs) for treating peripheral artery disease of the femoropopliteal segment has not been …
(BMSs) for treating peripheral artery disease of the femoropopliteal segment has not been …
Efficacy of a drug-eluting stent versus bare metal stents for symptomatic femoropopliteal peripheral artery disease: primary results of the EMINENT randomized trial
Y Goueffic, G Torsello, T Zeller, G Esposito… - …, 2022 - biblio.ugent.be
BACKGROUND: A clear patency benefit of a drug-eluting stent (DES) over bare metal stents
(BMSs) for treating peripheral artery disease of the femoropopliteal segment has not been …
(BMSs) for treating peripheral artery disease of the femoropopliteal segment has not been …
[PDF][PDF] Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT …
Y Gouëffic, G Torsello, T Zeller, G Esposito… - Circulation, 2022 - scholar.archive.org
BACKGROUND: A clear patency benefit of a drug-eluting stent (DES) over a bare metal
stent (BMS) for treating peripheral artery disease of the femoropopliteal segment has not …
stent (BMS) for treating peripheral artery disease of the femoropopliteal segment has not …
[PDF][PDF] Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT …
Y Gouëffic, G Torsello, T Zeller, G Esposito… - …, 2022 - backoffice.biblio.ugent.be
BACKGROUND: A clear patency benefit of a drug-eluting stent (DES) over bare metal stents
(BMSs) for treating peripheral artery disease of the femoropopliteal segment has not been …
(BMSs) for treating peripheral artery disease of the femoropopliteal segment has not been …
Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized …
Y Gouëffic, G Torsello, T Zeller, G Esposito… - CIRCULATION, 2022 - iris.unisr.it
A clear patency benefit of a drug-eluting stent (DES) over bare metal stents (BMSs) for
treating peripheral artery disease of the femoropopliteal segment has not been definitively …
treating peripheral artery disease of the femoropopliteal segment has not been definitively …